Table I.
Author, year | Cell source | Stimulant | Cytokines (concentration) | Relative increase in the number of cells (times) | Duration of culture (days) | Refs. |
---|---|---|---|---|---|---|
Duault et al, 2016 | PBMC | BrHPP | IL-2 (400 U/ml), IL-33 (100, 500 or 1,000 ng/ml) | 10-12 | 10 | (40) |
Klimpel et al, 2003 | PBMC | None | IL-2 (100 U/ml), IL-15 (1,000 U/ml) | 10-12 | 8 | (41) |
Kondo et al, 2011 | PBMC | Zoledronate (Zometa) | IL-2 (1,000 U/ml) | 12-16 | 14 | (24,42) |
Sato et al, 2009 | ||||||
Barcy et al, 2008 | PBMC | None | IL-2 (20 U/ml) IL-7 (100 U/ml) | 6-8 | 14 | (43) |
Rincon-Orozco et al, 2005 | PBMC | IPP | IL-2 (100 U/ml) | – | 14 | (44) |
Cabillic et al, 2010 | PBMC | BrHPP/Zoledronate (Zometa) | IL-2 (400 U/ml) | 12-14 | 14 | (45) |
Casetti et al, 2009 | PBMC | IPP | IL-2 (6.5 U/ml), IL-15 (10 ng/ml), TNF-α (1.7 ng/ml) | 6-8 | 10 | (46) |
Devilder et al, 2009 | PBMC | Phytohemagglutinin | None | 6-8 | – | (47) |
Tsai et al 2015 | Magnetically isolated γδ T cells | None | None | – | – | (48) |
McGill et al, 2016 | Magnetically isolated γδ T cells | None | IL-2 (10 U/ml) | 8-10 | – | (49) |
BrHPP, bromohydrin pyrophosphate; IL, interleukin; IPP, isopentenyl pyrophosphate; PBMC, peripheral blood mononuclear cell; TNF-α, tumor necrosis factor α.